• Home
• About us
• Contact

• News
• People
• Products
• Deals
• Organisations

• » Follow us on twitter!
• » Get Free Newsletter!

Organisation › Details

Evotec SE (FSE: EVT, MDA X/TecDAX)

Evotec is a drug discovery alliance and development partnership company focused on rapidly progressing innovative product approaches with leading pharmaceutical and biotechnology companies, academics, patient advocacy groups and venture capitalists. We operate worldwide providing the highest quality stand-alone and integrated drug discovery solutions, covering all activities from target-to-clinic to meet the industry's need for innovation and efficiency in drug discovery (EVT Execute). The Company has established a unique position by assembling top-class scientific experts and integrating state-of-the-art technologies as well as substantial experience and expertise in key therapeutic areas including neuroscience, diabetes and complications of diabetes, pain and inflammation, oncology and infectious diseases. On this basis, Evotec has built a broad and deep pipeline of more than 80 partnered product opportunities at clinical, pre-clinical and discovery stages (EVT Innovate). Evotec has established multiple long-term discovery alliances with partners including Bayer, CHDI, Sanofi or UCB and development partnerships with e.g. with Sanofi in the field of diabetes, with Pfizer in the field of tissue fibrosis and Celgene in the field of neurodegenerative diseases. *

 

	Start	2019-04-01 restructured
	Group	Evotec (Group)
	Predecessor	Evotec AG (FSE: EVT, TecDAX)
	Industry	drug discovery technology
	Industry 2	drug discovery services
	Person	Lanthaler, Werner (Evotec AG 200903– CEO before Intercell AG CFO before Austrian Industrial Assoc before McKinsey)
	Person 2	Spillner, Enno (Evotec 201607– CFO before 4SC CEO + CFO before BioM Venture Capital GmbH)
	Region	Hamburg
	Country	Germany
	City	n. a.
		Address record changed: 2019-04-16
Basic data	Employees	F: 1,001 to 5,000 (2018-12-31)
	Currency	EUR
	Annual sales	375,405,000 (revenues, consolidated (2018) 2018-12-31)
	Profit	84,056,000 (2018-12-31)
	Cash	109,055,000 (2018-12-31)
		* Document for �About Section�: Evotec AG. (5/31/18). "Press Release: Evotec Forms Academic Bridge »LAB591« with Arix Bioscience and Fred Hutchinson Cancer Research Center". Hamburg.
		Record changed: 2019-07-30

Advertisement

More documents for Evotec (Group)

• [1] Evotec SE. (7/25/19). "Press Release: P2X3 Antagonist Demonstrates Efficacy against Refractory Chronic Cough in Phase II (POC)". Hamburg....
• [2] Evotec SE. (7/15/19). "Press Release: Evotec Expands Its iPSC Platform. Acquired Assets from Ncardia AG". Hamburg....
• [3] Evotec SE. (7/8/19). "Press Release: Evotec and Venture Capital Consortium Form Breakpoint Therapeutics GmbH". Hamburg....
• [4] Nosopharm S.A.S.. (7/3/19). "Press Release: Nosopharm and Evotec Enter into Collaboration to Accelerate Development of Novel Antibiotics". Lyon & Hamburg....
• [5] Evotec SE. (7/3/19). "Press Release: Evotec Completes Acquisition of Just Biotherapeutics". Hamburg....
• [6] Evotec SE. (6/26/19). "Press Release: Evotec SE Places First Schuldschein (Promissory Note) Worth EUR 250 m". Hamburg....
• [7] MaRS Innovation. (6/11/19). "Press Release: LAB150 Adds Project with Focus on Mental Health". Toronto, ON....
• [8] Evotec SE. (6/10/19). "Press Release: Evotec Receives $23.8m Grant to Join the Global Fight against Tuberculosis". Hamburg....
• [9] Evotec SE. (6/5/19). "Press Release: Evotec and Celgene further Expand iPSC Collaboration including New Cell Type". Hamburg....
• [10] Evotec SE. (5/20/19). "Press Release: Evotec Jump-starts Biologics with Acquisition of Just Biotherapeutics". Hamburg....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

» top

» Imprint  |  » Data Privacy  |  » Contact  |  The use of this website requires to accept the » Disclaimer!   |  A project of [iito] Business Intelligence © 2002-2019. Made in Germany.